RecruitingNot ApplicableNCT05242419

A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery

A Multi-center, Randomized, Double-blinded, Placebo-controlled Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery


Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Enrollment

40 participants

Start Date

Jun 10, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To observe and study the clinical effect of Huperzine A Injection on reducing postoperative delirium in elderly patients undergoing non-cardiac surgery


Eligibility

Min Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Huperzine A Injection and a drug called Sodium Chloride Injection for people with delirium in old age, injection, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 75 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSodium Chloride Injection

0.9% Sodium Chloride Injection

DRUGHuperzine A Injection

Huperzine A Injection


Locations(1)

The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study

Wenzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05242419


Related Trials